A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age

  title={A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age},
  author={L. Chang and P. L. Lee and Constantin Theodore Yiannoutsos and Thomas Ernst and Christina M. Marra and Todd L. Richards and Dennis L. Kolson and Giovanni Schifitto and Jeffrey G. Jarvik and Eric Miller and Robert E. Lenkinski and G. Gonzalez and Bradford Navia and H. I. V. Mrs Consortium},

Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment

Findings indicate that despite the widespread use of HAART, HIV-associated cognitive impairment and brain injury persist in the setting of chronic and stable disease.

Factor analysis of proton MR spectroscopic imaging data in HIV infection: metabolite-derived factors help identify infection and dementia.

The results highlight the importance of white matter involvement in HIV-associated dementia and support the current pathogenesis model of glial cell proliferation in HIV infection, denoted by regional Cho elevations, and neuronal dysfunction and/or death, denoting by NAA decreases, associated with dementia.

7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests

Compared with asymptomatic subjects, symptomatic HIV-positive subjects had lower levels of NAA and glutamate, most notably in the frontal white matter, which also correlated with performance on neuropsychological tests.

Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART

It is shown for the first time that host and viral factors related to both current and past HIV status contribute to persisting cerebral metabolite abnormalities and provide a framework for further understanding neurological injury in the setting of chronic and stable disease.

Metabolic markers of neuronal injury correlate with SIV CNS disease severity and inoculum in the macaque model of neuroAIDS

The findings here support prevention of the encephalitic process, but suggest that suppressing the formation of multinucleated giant cells alone would be insufficient to prevent neuronal injury.

Neuronal-Glia Markers by Magnetic Resonance Spectroscopy in HIV Before and After Combination Antiretroviral Therapy

cART started during chronic HIV is associated with reduced neuronal-glia and inflammatory markers and Alterations in CHO are noted among individuals who remain impaired after 12 months of cART.

White matter damage, neuroinflammation, and neuronal integrity in HAND

Overall, HAND showed specific alterations (more aWM and inflammation; less gray matter volume and lower NAA); some MR measures differentiated less severe subtypes of HAND from HAD.

Imaging Neuroinflammation? A Perspective from MR Spectroscopy

The current results suggest that competing mechanisms can influence in vivo Cho and mI levels, and that elevations in these metabolites cannot necessarily be interpreted as reflecting a single underlying mechanism, including neuroinflammation.

Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy

Widespread progressive changes in the brain, including neuronal injury, occur in chronically HIV-infected persons despite stable antiretroviral treatment and virologic suppression and can lead to neurocognitive declines.

Magnetic Resonance Spectroscopy in HIV-Associated Brain Injury

This chapter describes the different methods used to perform magnetic resonance spectroscopy (MRS) studies of patients with HIV infection, reviews the major findings from the studies, and identifies



Metabolic characterization of AIDS dementia complex by spectroscopic imaging

Reduced NAA seems to indicate progressive neuronal injury or loss due to productive HIV infection in the brain and its clinical picture ADC, and may serve as an early quantitative marker of central nervous system involvement in AIDS.

1H MR Spectroscopy of the Brain in HIV-1-Seropositive Subjects: Evidence for Diffuse Metabolic Abnormalities

The absence of significant regional variation in metabolite ratios at the level of the centrum semiovale provides some evidence that abnormalities of cerebral metabolites in HIV-infected patients may be part of a diffuse process.

HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times.

ADC has a uniform pathologic metabolic pattern that affects NAA, MI, and Cho and proton MR spectroscopy with short echo times helps detect early abnormalities in clinically asymptomatic patients.

Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS

These objective, non-invasive techniques may be used for monitoring the neurological effects of antiretroviral drug therapy in patients with HADC.

Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy.

MRS appears to be of great interest in predicting responsiveness to antiretroviral drugs and detecting early any resistance to treatment, in patients displaying an NAA pattern whereas this treatment had no effect on the patients displaying the Cho pattern.

Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia.

FDG-PET scans provide quantitative measures of abnormal functional connectivity in HIV-seropositives-with or without AIDS or ADC, and appear to track the progression of CNS involvement in patients with subclinical neurologic or neuropsychologic dysfunction.

Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.

H-1 MR spectroscopy demonstrated biochemical abnormalities in patients with frontotemporal dementia and aided differentiation between patients with back-to-back dementia and Alzheimer disease.

Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings.

Combined MR imaging and spectroscopy provides closer relationships to clinical and immunologic measures of disease than either modality alone and augments the value of an MR imaging study.